-
US House faces test on sweeping Russia sanctions bill
-
IR-MED and Dice Technologies Announce collaboration to Evaluate and Advance Pressure-Injury Prevention Platform in Japan
-
British PM says to make 'difficult decisions' as inflation rises
-
Watts, Pitt, Cruz to light up Spain's top film festival
-
Global fuel price demos: a round-up
-
Toogood Gold's Table Mountain Sits in the Shadow of a Nevada Gold Rush
-
Leverate Launches MCP for Traders to Connect AI Assistants With Trading Platforms
-
MEXC July–August Security Report: 38.66M USDT in Risk Funds Intercepted, Futures Insurance Fund Hits 792M USDT
-
MEXC Launches $1M "Discover Your Wall Street DNA" Campaign to Help Traders Find Their Market Fit
-
Emporio Armani names Dario Vitale new creative director
-
Stocks edge higher ahead of US Fed rate call
-
EU to ban social media for under 13s, curb access until 15
-
BASIS.pro Expands On-Chain Infrastructure with XDC Network Partnership and Zypher DAO as Auto Earn Goes Live
-
Wildfires push endangered Sumatran elephants to brink: Indonesian NGO
-
Pickle-flavoured tart? AI inspires Japan's convenience stores
-
Bank of Japan set to raise rates under pressure from inflation, US
-
EU chief hosts Canada's Carney in push to 'deepen' alliance
-
EU chief to unveil social media, gaming curbs for under-15s
-
Meta chief pushes back on AI slowdown calls
-
'Resident Evil' film brings video game's ethos to the big screen
-
US Fed to deliver rate decision with markets betting on hike
-
i-payout Expands U.S. Money Transmitter Licensing Footprint and Advances European EMI Strategy
-
Sanders, Bannon warn of AI dangers in rare US left-right alignment
-
US Senate crypto bill collapses amid partisan deadlock
-
Empty benches as schools reopen in Venezuela's quake-hit Guaira
-
OpenAI, Anthropic and Google are working to create an AI standards body
-
Tiny English village holds 'independence' vote over asylum seeker housing
-
Protesting shepherds, farmers clash with Romanian police
-
US Treasury chief says to meet Chinese counterpart at weekend
-
Foundation Lets Ledger Users Switch to Open Source Without Starting Over
-
BingX Evolves into a Multi-Asset Trading Platform, Connecting Users to Global Opportunities
-
EU to propose curbing social media, online games for under 15s
-
International Trading Institute Expands Professional Trader Development Beyond the Master’s in Trading
-
FX Junction Reaches 40,600 Members and 26 Million Trades
-
Lake Energy Secures $80 Million for U.S. Renewable Energy Expansion
-
'We unleashed the beast': the world's fears and hopes about AI
-
Stocks drop, oil climbs and Treasury yields hit 19-year high
-
Hospitality leaders ask Burnham to halve VAT amid rising costs
-
SkySail Strategies Outperforms Wall Street's 30-Year Risk Standard With Proprietary AI Inference Model
-
Worcestershire invited to nominate groups for 2027 King’s volunteer award
-
Just add fish: Scientists pursue more rice, less disease in Senegal paddies
-
Berlin's run-down public spaces at heart of election campaign
-
Belgium completes outer structure of offshore energy island
-
'Widow's Bay' and 'The Pitt' win big at Emmy Awards
-
China retail sales growth weakens further in August
-
Most markets drop as oil extends gains ahead of expected US rate hike
-
In Kashmir, lake weeds mix with traditional art
-
Sri Lanka's famed beach shack battles demolition
-
'Widow's Bay' and 'The Pitt' take key Emmy awards
-
Vserv targets ₹1,000 crore revenue by 2030 through AI expansion
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
L.K.Baumgartner--CPN